Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...
Sanofi (SNY) has received Chinese regulatory approval for two rare hematology drugs, Qfitlia and Cablivi, significantly ...
Pharmaceutical Technology on MSN
China’s NMPA approves Sanofi’s rare haematologic disease treatments
China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...
With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...
Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism ...
Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...
Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback